跳至主要内容
临床试验/NCT04466618
NCT04466618已完成3 期

To Determine the Effect of Endogenous GLP-1 Secretion on Islet Function in People With and Without Type 2 Diabetes

Adrian Vella2 个研究点 分布在 1 个国家目标入组 23 人开始时间: 2021年4月15日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
Adrian Vella
入组人数
23
试验地点
2
主要终点
Change in Fasting Glucagon in the Presence or Absence of Exendin-9,39

研究概览

简要总结

GLP-1 is a hormone made by the body that promotes the production of insulin in response to GLP-1 is produced within the islets expressing prohormone convertase 1/3eating. However, there is increasing evidence that this hormone might help support the body's ability to produce insulin when diabetes develops. The purpose of this study is to determine the effect of endogenous GLP-1 secretion on insulin secretion in people with and without type 2 diabetes.

详细描述

Accumulating evidence suggests that in rodents and humans GLP-1 is synthesized within islets and may act locally in a paracrine fashion. Indeed, mice with genetic loss of intra-islet GLP-1 exhibit decreased insulin secretion and impaired response to metabolic stressors. 'Pancreatic' GLP-1 may contribute to the effects of DPP-4 inhibitors in rodents and humans. Antagonism of GLP1R with exendin-9,39 during fasting impairs the islet cell response to an I.V. glucose challenge. Islet GLP-1 content is increased in T2DM and in islets from non-diabetic humans exposed to hyperglycemia and Free Fatty Acids. These observations imply that paracrine GLP-1 secretion supports islet function in the presence of glucolipotoxicity. In this experiment we will examine the role of endogenous GLP-1 secretion in people with and without T2DM and during β-cell stress induced by FFA elevation.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Basic Science
盲法
None

入排标准

年龄范围
25 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Change in Fasting Glucagon in the Presence or Absence of Exendin-9,39

时间窗: Average concentration over the -30 to 0 minutes of study

Concentrations of glucagon Measured by immunoassay over the -30 to 0 minutes of study. On one study day subjects received saline, on the other exendin-9,39. The infusion commenced at -120 minutes.

次要结局

未报告次要终点

研究者

发起方
Adrian Vella
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Adrian Vella

Principal Investigator

Mayo Clinic

研究点 (2)

Loading locations...

相似试验